Trial Profile
Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Acronyms MARBLE; Trans-MARBLE
- Sponsors AIO Studien gGmbH
- 18 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 06 Nov 2015 New trial record